Therefore, the T cell protective effects of therapeutics blocking immune checkpoints such as PD-1 and CTLA-4 pathways during sepsis could also involve metabolic reprogramming and re-invigoration of the glycolytic pathway, which will be an interesting topic for future studies. Here, PDCD1 is linked to Sepsis.